Oncology Central

Olaparib becomes the first drug approved for BRCA breast cancer

The FDA has expanded the label for AstraZeneca’s oral PARP inhibitor Lynparza (olaparib) to include the treatment of patients with metastatic breast cancer whose disease is associated with a BRCA gene mutation.

The decision makes olaparib the first and only approval for a PARP inhibitor for use beyond ovarian cancer. It is the first time any drug has been approved specifically to treat BRCA-mutated breast cancer.

The approval is a result of the highly promising results published from the

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.